Genomic alterations associated with loss of heterozygosity for TP53 in Li-Fraumeni syndrome fibroblasts

British Journal of Cancer

Volumn 83, Issue 4, 2000, Pages 467-472

  Burt, E C ^a   James, L A ^a   Greaves, M J ^a   Birch, J M ^b   Boyle, J M ^a   Varley, J M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

CGH; Fibroblasts; Li fraumeni syndrome; LOH; TP53

Indexed keywords

PROTEIN P53;

ANEUPLOIDY; ARTICLE; CELL CYCLE; CHROMOSOME 17P; CHROMOSOME 4Q; CHROMOSOME 6Q; CHROMOSOME 9P; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FAMILIAL CANCER; FIBROBLAST; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; MICROSATELLITE INSTABILITY; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

EID: 0033931246     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2000.1292     Document Type: Article

References (31)

1. Bentz M, Plesch A, Stilgenbauer S, Dohner H and Lichter P (1998) Minimal sizes of deletions detected by comparative genomic hybridization. Genes Chromosomes Cancer 21: 172-175
2. Bertram MJ, Berube NG, Hang-Swanson X, Ran Q, Leung JK, Bryce S, Spurgers K, Bick RJ, Baldini A, Ning Y, Clark LJ, Parkinson EK, Barrett JC, Smith JR and Pereira Smith OM (1999) Identification of a gene that reverses the immortal phenotype of a subset of cells and is a member of a novel family of transcription factor-like genes. Mol Cell Biol 19: 1479-1485
3. Birch JM, Hartley AL, Tricker KJ, Prosser J, Condie A, Kelsey AM, Harris M, Morris Jones PH, Binchy A, Crowther D, Craft AW, Eden OB, Evans GR, Thompson E, Mann JR, Martin J, Mitchell ELD and Santibanez-Koref MF (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Res 54: 1298-1304
4. Boyle JM, Mitchell ELD, Greaves MJ, Roberts SA, Tricker K, Burt E, Varley JM, Birch JM and Scott D (1998) Chromosome instability is a predominant trait of fibroblasts from Li-Fraumeni families. Br J Cancer 77: 2181-2192
5. 1 arrest is not defective in fibroblasts from Li-Fraumeni families without TP53 mutations. Br J Cancer 79: 1657-1664
6. Bryce SD, Forsyth NR, Fitzsimmons SA, Clark LJ, Bertram MJ, Cuthbert AP, Newbold RF, Pereira-Smith OM and Parkinson EK (1999) Genetic and functional analyses exclude mortality factor 4 (MORF4) as a keratinocyte senescence gene. Cancer Res 59: 2038-2040
7. Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A, Mao L, Herath J, Jenkins R, Westra W, Rutter JL, Buckler A, Gabrielson E, Tockman M, Cho KR, Hedrick L, Bova GS, Isaacs W, Koch W, Schwab D and Sidransky D (1995) Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11: 210-212
8. Couch FJ, Wang X-Y, Wu G-J, Qian J, Jenkins RB and James CD (1999) Localization of PS6K to chromosomal region 17q23 and determination of its amplification in breast cancer. Cancer Res 59: 1408-1411
9. Dib C, Faure S, Fizames C, Samson D, Drouot N, Vignal A, Millasseau P, Marc S, Hazan J, Seboun E, Lathrop M, Gyapay G, Morissette J and Weissenbach J (1996) A comprehensive genetic map of the human genome based on 5,264 microsatellites [see comments]. Nature 380: 152-154
10. Hollstein M, Sidransky D, Vogelstein B and Harris CC (1991) p53 mutations in human cancers. Science 253: 49-53
11. James LA (1999) Comparative genomic hybridisation as a tool in tumour cytogenetics. J Pathol 187: 385-395
12. James LA, Mitchell ELD, Menasce L and Varley JM (1997) Comparative genomic hybridisation of ductal carcinoma in situ of the breast: identification of regions of DNA amplification and deletion in common with invasive breast carcinoma. Oncogene 14: 1059-1065
13. Kallioniemi A, Kallioniemi O-P, Sudar D, Rutovitz D, Gray JW, Waldman F and Pinkel D (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumours. Science 258: 818-821
14. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS, Johnson BE and Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumour types. Science 264: 436-440
15. Knuutila S, Bjorkvist A-M, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius V-M, Vidgren V and Zhu Y (1998) DNA copy number amplifications in human neoplasms. Am J Pathol 152: 1107-1123
16. Lane DP and Crawford LV (1979) T antigen is bound to a host protein in SV40-transformed cells. Nature 278: 261-263
17. Levine AJ, Momand J and Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453-456
18. Li FP, Fraumeni JF, Jr Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA and Miller RW (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48: 5358-5362
19. INK4A transcript. Cancer Res 55: 2995-2997
20. Morelli C, Sherratt T, Trabanelli C, Rimessi P, Gualandi F, Greaves MJ, Negrini M, Boyle JM and Barbanti-Brodano G (1997) Characterization of a 4-Mb region at chromosome 6q21 harboring a replicative senescence gene. Cancer Res 57: 4153-4157
21. INK4 expression. Oncogene 13: 1259-1268
22. Parsons R, Myeroff LL, Liu B, Willson JK, Markowitz SD, Kinsler KW and Vogelstein B (1995) Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 55: 5548-5550
23. Piper J, Rutovitz D, Sudar D, Kallioniemi A, Kallioniemi OP, Waldman FM, Gray JW and Pinkel D (1995) Computer image analysis of comparative genomic hybridization. Cytometry 19: 10-26
24. Quelle DE, Zindy F, Ashmun RA and Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000
25. INK4 expression and telomere length during spontaneous immortalization of Li-Fraumeni syndrome fibroblasts. Mol Cell Biol 15: 4745-4753
26. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G and Kamb A (1995) Complex structure and regulation of the P16 (MTSI) locus. Cancer Res 55: 2988-2994
27. Tainsky MA, Bischoff FZ and Strong LC (1995) Genomic instability due to germline p53 mutations drives preneoplastic progression toward cancer in human cells. Cancer Metastasis Rev 14: 43-48
28. Varley JM, McGown G, Thorncroft M, Santihanez-Koref MF, Kelsey AM, Tricker KJ, Evans DGR and Birch JM (1997) Germ-line mutations of TP53 in Li-Fraumeni families: an extended study of 39 families. Cancer Res 57: 3245-3252
29. Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G, Evans DGR, Harris M, Kelsey AM and Birch JM (1999) Are there low penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 65, 995-1006
30. Velasco-Miguel S, Buckbinder L, Jean P, Gelbert L, Talbott R, Laidlaw J, Seizinger B and Kley N (1999) PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene 18: 127-137
31. Wahl GM, Linke SP, Paulson TG and Huang L-C (1997) Maintaining genetic stability through TP53 mediated checkpoint control. Cancer Surv 29: 183-219